Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of Orally Administered TU2670 in Subjects With Mod to Severe Endometriosis-Associated Pain

NCT05138562 is registered in ClinicalTrials.gov with TiumBio Co., Ltd. as lead sponsor.

NCT NCT05138562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05138562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of Orally Administered TU2670 in Subjects With Mod to Severe Endometriosis-Associated Pain
Lead sponsor
TiumBio Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
August 19, 2021
Completion date
August 5, 2024
Enrollment
86 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis